An integrated outsourcing practice of nonclinical LC–MS bioanalysis and toxicokinetics at Novartis small molecule drug development

Abstract

With decommissioning of internal regulated bioanalytical (BA) and toxicokinetic (TK) capabilities, Novartis has relied on external service providers (ESPs) for all nonclinical LC–MS BA and majority of the associated TK work since 2017. This paper outlines an integrated outsourcing practice of the Novartis nonclinical LC–MS BA/TK group, which covers the roles and responsibilities of Novartis nonclinical LC–MS BA/TK expert scientific monitors, selection of ESPs for Novartis nonclinical LC–MS BA/TK studies, qualification of BA/TK ESPs, study conduct and completion, ESP oversight and evaluation, issue mitigation, and future perspectives.